Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Combined label-free/fluorescence platform based on Bloch surface waves biochips for cancer biomarker detection

: Danz, N.; Sinibaldi, A.; Allegretti, M.; Sepe, E.; Munzert, P.; Giacomini, P.; Michelotti, F.


Danielli, A. ; Society of Photo-Optical Instrumentation Engineers -SPIE-, Bellingham/Wash.:
Frontiers in Biological Detection: from Nanosensors to Systems XI : 3-4 February 2019, San Francisco, California, United States
Bellingham, WA: SPIE, 2019 (Proceedings of SPIE 10895)
ISBN: 978-1-5106-2433-7
ISBN: 978-1-5106-2432-0
Paper 106850X, 9 S.
Conference "Frontiers in Biological Detection - From Nanosensors to Systems" <11, 2019, San Francisco/Calif.>
Biophotonics, Biomedical Optics, and Imaging Conference (BIOS) <2019, San Francisco/Calif.>
Photonics West Conference <2019, San Francisco/Calif.>
Fraunhofer IOF ()

A biosensor platform based on Bloch Surface Waves and operating in angular interrogation mode is applied to the detection of a clinical biomarker (HER2-neu/ERBB2) related to breast cancer initiation/progression. Preparing regions for specific recognition of different proteins as well as a reference on the biochip enables to correct the signal for nonspecific effects. Additionally, label-free analysis and surface wave enhanced fluorescence detection can be applied and compared directly on the platform. Cell lysates with high and low expression levels of ERBB2 are analyzed. Comparing the signals of such ERBB2 positive and negative samples estimates the limit of detection at 1.7 ng/mL. This is well below the threshold of 15 ng/mL set by the FDA for clinically useful ERBB2 detection in human serum, demonstrating that 1DPC-based biochips are attractive candidates for breast cancer detection/monitoring.